HIV-1 vaccines and adaptive trial designs

In Regulation and Policy by Freya SmaleLeave a Comment

download, hiv vaccine

HIV-1 vaccines and adaptive trial designs presented by Dr James Kublin, Executive Director, HVTN, Fred Hutchinson Cancer Research Center.

The presentation details the following:

Objectives of the Research Trial Design

· Primary objective: For each vaccine regimen, to evaluate VE against HIV infection within 18 months of randomization [i.e., VE(0-18)]

· Secondary objectives:

o To evaluate durability of VE out to 36 months for each regimen showing reliable evidence for positive VE(0-18)

o To expeditiously and rigorously evaluate immune correlates protection if any of the vaccine regimens show reliable evidence for VE(0-18) > 0%

o To compare VE among the vaccine regimens

· An adaptive 2-stage design for each vaccine regimen:

o Stage 1 evaluates VE(0-18)

o Stage 2 evaluates longer-term VE(t), and occurs if and only if the trial provides reliable evidence for VE(0-18) > 0%


The Adaptations Follow FDA Guidance Principles

· Adaptations can be done safely without sacrificing design integrity if:

o Planned: Adaptation triggered by pre-specified deterministic rules [may depend on VE]

o Independent of treatment: Adaptation unplanned, but is based on treatment-blinded data

· The developed designs are in the safe zone, adhering to the FDA guidance document Adaptive Design Clinical Trials for Drugsand Biologics February 2010

And more…

Download the full presentation here!

To find out more about our presentations click here >

For more updates on the vaccines industry, follow us on Twitter:  @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Comment

Current ye@r *